All In Biotech

Drug Trial Radar · NCT01097044

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

77

Actual

Start

Apr 2010

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized placebo-controlled study to be conducted in two parallel study arms for a six month period (three doses). Approximately 10 eligible patients per center will be enrolled and will receive afamelanotide (16 mg implants) or placebo according to the following dosing regimen: * Group A will be administered afamelanotide implants on Days 0, 60 and 120 * Group B will be administered placebo implants on Days 0, 60 and 120 To determine eligibility for study inclusion, patients will undergo a screening evaluation 7 to 14 days prior to the administration of the first dose. The number and severity of phototoxic reactions will be determined Days 60, 120, and 180. Quality of life will be measured using the EPP specific questionnaire (EPP-QoL) every 60 days and the DLQI questionnaire every 7 days, beginning at Day 0 until Day 180. Participants will visit the clinic on Days 60, 120 and 180 for assessments of adverse events.

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • AfamelanotideDrug

    One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)

  • PlaceboDrug

    One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in Direct Sunlight Between 10:00-15:00 on Pain-free DaysTime frame: Daily for 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • University of California, San Francisco

    San Francisco, California

  • Mt. Sinai

    New York, New York

  • Carolina's Medical Center Cannon Research

    Charlotte, North Carolina

  • University of Texas

    Galveston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.